| Literature DB >> 35447801 |
Sean Araújo1, Janaína Seibert1, Ana Ruani1, Ricardo Alcántara-de la Cruz2, Artur Cruz1, Alana Pereira1,3, Doraí Zandonai1, Moacir Forim1, Maria Fátima Silva1, Odair Bueno4, João Fernandes1.
Abstract
Atta and Acromyrmex are the main genera of leaf-cutting ants present in North and South America, causing extensive damage to agroforestry. Control of the ants requires high handling costs with few effective methods available to decrease the losses. The symbiosis between the leaf-cutting ants and the fungus Leucoagaricus gongylophorus is essential for ant nest survival. Therefore, L. gongylophorus may be a key target in controlling leaf-cutting ants, since its reduction may cause an imbalance in the symbiosis necessary to maintain the nest. Among the options for natural fungal control, plant species are considered important sources of compounds belonging to several classes of natural products that show potential as antifungal agents. This review also presents studies that establish that the antagonist fungi from the Escovopsis and Trichoderma genera effectively reduce the development of L. gongylophorus. The development of nanostructured delivery systems, which have shown advantages over conventional formulations, is suggested for ant control; no commercial nanotechnology-based product has yet been developed, and this appears to be a new approach for future studies.Entities:
Keywords: antifungal activity; biological control; chemical control; natural products; pesticide; synthetic compound
Year: 2022 PMID: 35447801 PMCID: PMC9029082 DOI: 10.3390/insects13040359
Source DB: PubMed Journal: Insects ISSN: 2075-4450 Impact factor: 3.139
Figure 1Symbiotic relationship between leaf-cutting ants and Leucoagaricus gongylophorus symbiotic fungus: (a) Gongylidia produced in the fungus garden are the main source of food for the ant larvae; (b) fungus enzymes such as amylase are responsible for the biodegradation of organic material into glucose, the main food source for the worker ants; (c) leaf-cutting ants produce antibiotic compounds that protect the fungus garden against harmful agents; (d) pathogenic microorganisms such Escovopsis fungal genera.
Plant extracts and essential oils with potential antifungal effects against Leucoagaricus gongylophorus by in vitro assays.
| Species | Extract | Part of Plant | Inhibitory Effect | Reference |
|---|---|---|---|---|
|
| Ethanol extract | Leaves | 500 µg/spot–5 mm * (B) | [ |
|
| Hexane extract | Leaves | 25 mg/mL–81% (C) | [ |
|
| - | Bulbs | IC50–1241.55 μg/mL (A)/2000 µg/mL–0.0 to 0.02 g ** (D)/2000 µg/mL–Fungistatic (E) | [ |
|
| - | Seed pods | IC50–358.36 μg/mL (A)/2000 µg/mL–0.0 g ** (D)/2000 µg/mL–Fungicidal (E) | [ |
|
| Ethanol extract | - | 500 µg/spot–15 mm * (B)/MIC–1.95 µg/mL (F) | [ |
|
| Ethanol extract | - | 500 µg/spot–5 mm * (B) | [ |
|
| Ethanol extract | - | 500 µg/spot–5 mm * (B) | [ |
|
| Ethanol extract | - | 500 µg/spot–10 mm * (B) | [ |
|
| Ethanol extract | Leaves | 0.1% | [ |
|
| Ethanol extract | Leaves | 0.1% | [ |
|
| Dichloromethane extract | Fruits | 1000 mg/mL–80% (A) | [ |
| Hexane extract | Branches | 1000 mg/mL–80% (A) | ||
| Dichloromethane extract | Branches | 1000 mg/mL–40% (A) | ||
| Hexane extract | Leaves | 1000 mg/mL–20% (A) | ||
| Dichloromethane extract | Leaves | 1000 mg/mL–20% (A) | ||
|
| Hexane extract | Leaves | 100 mg/mL–100% (A) | [ |
|
| Ethanol extract | - | 500 µg/spot–10 mm * (B) | [ |
|
| Ethanol extract | - | 500 µg/spot–5 mm * (B)/MIC–7.8 µg/mL (F) | [ |
|
| Ethanol extract | - | 500 µg/spot–5 mm * (B) | [ |
|
| - | Green fruits | IC50−2262.29 μg/mL (A)/2000 µg/mL–0.02 to 0.05 g ** (D)/2000 µg/mL–Fungistatic (E) | [ |
|
| - | Leaves | IC50−553.32 μg/mL (A)/2000 µg/mL–0.0 g ** (D)/2000 µg/mL–Fungicidal (E) | [ |
|
| Hexane extract | Leaves | 25 mg/mL–96% (C) | [ |
|
| Essential oil | Leaves | IC50−104.8 μL/L # (A)/IC50–217.9 µL/L ## (A) | [ |
| Essential oil | Leaves | IC50−145.1 μL/L # (A)/IC50–238.1 µL/L ## (A) | ||
|
| Dichloromethane extract | Stems | 1000 µg/mL–10% (A) | [ |
|
| Ethanol extract | Leaves | IC50−102 ppm (A) | [ |
| Essential oil | Leaves | 1000 ppm–100% (A) | ||
|
| Ethanol extract | - | 500 µg/spot–15 mm * (B)/MIC–7.8 µg/mL (F) | [ |
|
| Methanol extract | Stems | 1000 μg/mL–80% (A) | [ |
| Methanol extract | Leaves | 1000 μg/mL–80% (A) | ||
| Methanol extract (hexane fraction) | Leaves | 500 μg/mL–80% (A) | ||
|
| - | Leaves | IC50−251.51 μg/mL (A)/500 µg/mL–0.0 g ** (D)/500 µg/mL–Fungicidal (E) | [ |
|
| Chloroform extract | Leaves | 60 mg/mL–60% (A) | [ |
| Methanol extract | Leaves | 60 mg/mL–60% (A) | ||
| Methanol + Chloroform extract | Leaves | 60 + 60 mg/mL–>80% (A) | ||
| Chloroform extract | Leaves (30 days old) | 60 mg/mL–60% (A) | ||
| Chloroform extract | Leaves (60 days old) | 60 mg/mL–60% (A) | ||
| Chloroform extract | Green leaves (90 days old) | 60 mg/mL–40% (A) | ||
| Chloroform extract | Yellow leaves (90 days old) | 60 mg/mL–60% (A) | ||
| Chloroform extract | Green fruit | 30 mg/mL–40% (A) | ||
| Chloroform extract | Ripe fruit | 30 mg/mL–60% (A) | ||
| Chloroform extract | Green seed | 30 mg/mL–60% (A) | ||
| Chloroform extract | Ripe seed | 30 mg/mL–60% (A) | ||
|
| Ethanol extract | - | 500 µg/spot–5 mm * (B) | [ |
|
| Ethanol extract | - | 500 µg/spot–10 mm * (B) | [ |
Antifungal assay: (A) agar assay mycelium growth; (B) bioautography assay; (C) fungal biomass reduction by agar assay; (D) fungal biomass reduction by broth assay; (E) MTT assay; (F) broth microdilution assay. MIC: minimum inhibitory concentration. IC50: concentration that inhibits 50% of the fungal growth. * Mean inhibition area. ** Fungus weight. # Fumigation assay. ## Contact assay.
Microorganisms extracts with potential antifungal effects against Leucoagaricus gongylophorus by in vitro assays.
| Microorganism | Strain | Extract | Inhibitory Effect (Antifungal Assay) | Reference |
|---|---|---|---|---|
|
| LESF596 + Absence of | Crude extract | 3–5 cm2 * (A) | [ |
| LESF596 + Presence of | Crude extract | 3–5 cm2 * (A) | ||
| LESF599 + Absence of | Crude extract | 4–5 cm2 * (A) | ||
| LESF599 + Presence of | Crude extract | 4–5 cm2 * (A) | ||
| LESF017 + Absence of | Crude extract | 3–5 cm2 * (A) | [ | |
| LESF017 + Presence of | Crude extract | 2–3 cm2 * (A) | ||
| LESF019 + Absence of | Crude extract | 4–5 cm2 * (A) | ||
| LESF019 + Presence of | Crude extract | 3–4 cm2 * (A) | ||
| LESF021 + Absence of | Crude extract | 2–4 cm2 * (A) | ||
| LESF021 + Presence of | Crude extract | 1–3 cm2 * (A) | ||
| LESF023 + Absence of | Crude extract | 4–6 cm2 * (A) | ||
| LESF023 + Presence of | Crude extract | 3–5 cm2 * (A) | ||
| LESF033 + Absence of | Crude extract | 1–3 cm2 * (A) | ||
| LESF033 + Presence of | Crude extract | 1–2 cm2 * (A) | ||
| LESF039 + Absence of | Crude extract | 3–5 cm2 * (A) | ||
| LESF039 + Presence of | Crude extract | 3–4 cm2 * (A) | ||
| LESF040 + Absence of | Crude extract | 4–6 cm2 * (A) | ||
| LESF040 + Presence of | Crude extract | 3–5 cm2 * (A) | ||
| LESF041 + Absence of | Crude extract | 3–5 cm2 * (A) | ||
| LESF041 + Presence of | Crude extract | 5–6 cm2 * (A) | ||
| LESF043 + Absence of | Crude extract | 4–5 cm2 * (A) | ||
| LESF043 + Presence of | Crude extract | 3–4 cm2 * (A) | ||
| LESF045 + Absence of | Crude extract | 1–3 cm2 * (A) | ||
| LESF045 + Presence of | Crude extract | 3–5 cm2 * (A) |
Antifungal assay: (A) agar assay mycelium growth. * Fungal growth area.
Isolated compounds with potential antifungal effects against Leucoagaricus gongylophorus by in vitro assays.
| Compound | Class | Species (Part) | Characterization Method | Inhibitory Effect | Reference |
|---|---|---|---|---|---|
| 2- | Alkaloid | 1H NMR, 13C NMR, and EIMS | 100 μg/mL–50% (A) | [ | |
| 3β-Hydroxystigmast-5-en-7-one ( | Steroid | - | 60 µg/mL–20% (A) | [ | |
| 7-Hydroxy-3-(1′1′-dimethylallyl)-8-methoxycoumarin ( | Coumarin | 1H NMR, 13C NMR, MS and IR | 75 µg/mL–80% (A) | [ | |
| Angelicin ( | Coumarin | 1H NMR, 13C NMR, MS and IR | 72 µg/mL–40% (A) | [ | |
| Antimycin A1 ( | Macrolide | LC-ESI-MS | 5.8 nmol–+ * (B) | [ | |
| Antimycin A2 ( | Macrolide | LC-ESI-MS | 5.8 nmol–+ * (B) | [ | |
| Antimycin A3 ( | Macrolide | LC-ESI-MS | 5.8 nmol–+ * (B) | [ | |
| Antimycin A4 ( | Macrolide | LC-ESI-MS | 5.8 nmol–+ * (B) | [ | |
| Argentilactone ( | Fatty acid lactone derivative | 1H NMR, 13C NMR, and GC-MS | MIC–0.90 µg/mL (C) | [ | |
| Caffeine ( | Alkaloid | - | - | 0.50% | [ |
| Caryophyllene epoxide ( | Terpene | GC-MS and 13C NMR | 3 mg/mL–100% (A) | [ | |
| Citral ( | Terpene | GC-MS and GC-FID | IC50−31.7 μL/L # (A)/IC50−289.9 µL/L ## (A) | [ | |
| (2R,3R)-2,3-Di-(3′,4′-dimethoxybenzyl)-butyrolactone ( | Lignan | - | 200 μg/mL–20% (A) | [ | |
| (2R,3R)-3-(3″,4″-Dimethoxybenzyl)-2-(3′,4′-methylenedioxybenzyl)-butyrolactone ( | Lignan | - | 210 μg/mL–60% (A) | [ | |
| Dictamine ( | Alkaloid | - | 40 µg/mL–40% (A) | [ | |
| Dillapiole ( | Phenylpropanoid | GC-MS, 1H NMR, 13C NMR, and HMBC | IC50−38 ppm (A) | [ | |
| Epigalgavrin ( | Lignan | - | 200 μg/mL–>80% (A) | [ | |
| Eudesmin ( | Lignan | - | 160 μg/mL–40% (A) | [ | |
| Flindersiamine ( | Alkaloid | 1H NMR, 13C NMR, HMBC, and X-ray | 100 μg/mL–50% (A) | [ | |
| Isopimpinellin ( | Coumarin | 1H NMR, 13C NMR, MS, and IR | 80 µg/mL–100% (A) | [ | |
| Isopulegol ( | Terpene | GC-MS and GC-FID | IC50−150.1 μL/L # (A)/IC50−696.8 µL/L ## (A) | [ | |
| Kokusagine ( | Alkaloid | 1H NMR and 13C NMR | 100 μg/mL–100% (A) | [ | |
| Maculine ( | Alkaloid | 1H NMR and 13C NMR | 100 μg/mL–50% (A) | [ | |
| Philygenol ( | Lignan | - | 200 μg/mL–20% (A) | [ | |
| Platydesmine ( | Alkaloid | - | 50 µg/mL–80% (A) | [ | |
| Quebracho tannin ( | Tannin | - | - | 0.25% | [ |
| Sesamin ( | Lignan | - | 70 μg/mL–>80% (A) | [ | |
| Skimmianine ( | Alkaloid | 1H NMR and 13C NMR | 100 μg/mL–80% (A) | [ | |
| Suberosin ( | Coumarin | 1H NMR, 13C NMR, MS, and IR | 64 µg/mL–100% (A) | [ | |
| Syringaldehyde ( | Benzaldehyde | - | 50 µg/mL–80% (A) | [ | |
| Tannic acid ( | Tannin | - | - | 0.25% | [ |
| Umbelliferone ( | Coumarin | 1H NMR, 13C NMR, MS, and IR | 65 µg/mL–60% (A) | [ | |
| Vanillic acid ( | Phenolic acid | - | 50 µg/mL–80% (A) | [ | |
| Xanthoxyletin ( | Coumarin | 1H NMR, 13C NMR, MS, and IR | 70 µg/mL–100% (A) | [ | |
| Xanthyletin ( | Coumarin | 1H NMR, 13C NMR, MS, and IR | 25 µg/mL–100% (A) | [ |
Antifungal assay: (A) agar assay mycelium growth; (B) agar diffusion assay; (C) broth microdilution assay; (D) polyphenol oxidase activity; (E) fungal biomass reduction by broth assay. MIC: Minimum inhibitory concentration. IC50: concentration that inhibits 50% of the fungal growth. * Presence of antifungal effect (percentage inhibition not reported by the author). # Fumigation assay. ## Contact assay. & Relative optical density. && Fungal biomass.
Figure 2Chemical structure of natural compounds with potential antifungal effects against Leucoagaricus gongylophorus.
Synthetic compounds with potential antifungal effects against Leucoagaricus gongylophorus by in vitro assays.
| Compound | Class | Characterization Method | Inhibitory Effect (Antifungal Assay) | Reference |
|---|---|---|---|---|
| 1-(3,4-Methylenedioxybenzyloxy)ethane ( | Piperonyl-alkane | 1H NMR, 13C NMR, and EIMS | 330 μg/mL–80% (A) | [ |
| 1-(3,4-Methylenedioxybenzyloxy)butane ( | Piperonyl-alkane | 1H NMR, 13C NMR, and EIMS | 170 μg/mL–100% (A) | |
| 1-(3,4-Methylenedioxybenzyloxy)hexane ( | Piperonyl-alkane | 1H NMR, 13C NMR, and EIMS | 160 μg/mL–100% (A) | |
| 1-(3,4-Methylenedioxybenzyloxy)octane ( | Piperonyl-alkane | 1H NMR, 13C NMR, and EIMS | 15 μg/mL–80% (A) | |
| 1-(3,4-Methylenedioxybenzyloxy)decane ( | Piperonyl-alkane | 1H NMR, 13C NMR, and EIMS | 100 μg/mL–20% (A) | |
| N-Piperidine-3-(3,4-methylenedioxyphenyl)-2-(E)-propenamide ( | Piperonyl-amide | 1H NMR, 13C NMR, MS, IR, and TLC | 50 µg/mL–100% (A) | [ |
| N,N-Diethyl-3-(3,4-methylenedioxyphenyl)-2-(E)-propenamide ( | Piperonyl-amide | 1H NMR, 13C NMR, MS, IR, and TLC | 50 µg/mL–100% (A) | |
| N-Pyrrolidine-3-(3,4-methylenedioxyphenyl)-2-(E)-propenamide ( | Piperonyl-amide | 1H NMR, 13C NMR, MS, IR, and TLC | 100 µg/mL–100% (A) | |
| N-(2-Methylbutyl)-3-(3,4-methylenedioxyphenyl)-2-(E)-propenamide ( | Piperonyl-amide | 1H NMR, 13C NMR, MS, IR, and TLC | 100 µg/mL–80% (A) | |
| N-Morpholine-3-(3,4-methylenedioxyphenyl)-2-(E)-propenamide ( | Piperonyl-amide | 1H NMR, 13C NMR, MS, IR, and TLC | 100 µg/mL–40% (A) | |
| N-Aniline-3-(3,4-methylenedioxyphenyl)-2-(E)-propenamide ( | Piperonyl-amide | 1H NMR, 13C NMR, MS, IR, and TLC | 100 µg/mL–20% (A) | |
| Hexanoic acid ( | Saturated fatty acid | - | 100 µg/mL–100% (A) | [ |
| Heptanoic acid ( | Saturated fatty acid | - | 100 µg/mL–100% (A) | |
| Octanoic acid ( | Saturated fatty acid | - | 100 µg/mL–100% (A) | |
| Nonanoic acid ( | Saturated fatty acid | - | 100 µg/mL–100% (A) | |
| Decanoic acid ( | Saturated fatty acids | - | 100 µg/mL–100% (A) | |
| Undecanoic acid ( | Saturated fatty acid | - | 100 µg/mL–100% (A) | |
| Lauric acid ( | Saturated fatty acid | - | 100 µg/mL–100% (A) |
Antifungal assay: (A) agar assay mycelium growth.
Figure 3Chemical structure of synthetic compounds with potential antifungal effect against Leucoagaricus gongylophorus.
Figure 4Relationship of the percentage of inhibitory effect on Leucoagaricus gongylophorus growth according to the concentration of extracts (A), isolated natural compounds (B), and synthetic compounds (C). Graph obtained only from results expressed as a percentage inhibitory effect. Other data expressions were excluded due to the difficulty of comparison, but can be found in Table 1, Table 2, Table 3 and Table 4. * The most active extract was selected for species with more than one type of extract.
Microorganisms with potential antifungal effects against Leucoagaricus gongylophorus by in vitro assays.
| Organism | Strain | Inhibitory Effect (Antifungal Assay) | Reference |
|---|---|---|---|
|
| C1 | 26% (A) | [ |
|
| LESF596 | 56% (A) | [ |
| LESF599 | 45% (A) | ||
| AP090209–01 | + * (A) | [ | |
| AP090225-01 | + * (A/B/C) | ||
| AP090731-01 | + * (A/C) | ||
| AP100526-01 | + * (A/B/C) | ||
| DE090731-01 | + * (A/C) | ||
| LD100306-01 | + * (B/C) | ||
| RM090730-01 | + * (B) | ||
| RM090730-02 | + * (A/B/C) | ||
| LESF017 | 78% (A) | [ | |
| LESF043 | 70% (A) | ||
| LESF041 | 68% (A) | ||
| LESF039 | 65% (A) | ||
| LESF019 | 64% (A) | ||
| LESF021 | 62% (A) | ||
| LESF045 | 61% (A) | ||
| LESF033 | 59% (A) | ||
| LESF040 | 58% (A) | ||
| LESF023 | 56% (A) | ||
|
| CBS 810.71 | 68% (A) | [ |
| A088 | 67% (A) | ||
| A086 | 43% (A) | ||
| G-56 | 9% (A) | [ | |
| G-55 | 10% (A) | ||
| LESF130 | 8.71 ± 1.85 mm² ** (A) | [ | |
| LESF125 | 8.22 ± 1.64 mm² ** (A) | ||
| LESF127 | 8.80 ± 1.60 mm² ** (A) | ||
|
| T-83 | 1% (A) | [ |
|
| T-21 | 22% (A) | [ |
| T-86 | 30% (A) | ||
|
| HEP4 | 67.37% (A) | [ |
| HEP12 | 69.78% (A) | ||
| HEP20 | 58.03% (A) | ||
|
| T-28 | 11% (A) | [ |
| T-19 | 32% (A) | ||
| T-26 | 53% (A) | ||
| T-20 | 6% (A) | ||
| T-30 | 28% (A) | ||
| T-22 | 4% (A) | [ | |
| T-27 | 4% (A) | ||
| T-24 | 9% (A) | ||
| T-29 | 42% (A) | ||
| T-109 | 47% (A) | ||
| T-110 | 9% (A) | ||
| T-71 | 19% (A) | ||
|
| T-25 | 21% (A) | [ |
| T-23 | 33% (A) |
Antifungal assay: (A) agar assay mycelium growth; (B) fungus garden inhibitory bioassay; (C) sub-colony bioassay. * Presence of antifungal effect (percentage inhibition not reported by the author). ** Fungal mycelium growth area informed by the author (percentage calculated: LESF130–48%; LESF125–51%; LESF127–48%).
Figure 5Different types of antifungal methodologies performed on Leucoagaricus gongylophorus according to each decade.